Laying Out Analysis of Raludotatug Deruxtecan Dose Optimisation in Patients with Platinum-Resistant Ovarian Cancer

  • Overviewing R-DXd design and mechanism of action
  • Presenting clinical activity of R-DXd in patients with platinum-resistant ovarian cancer (PROC) from Phase I and Phase II/III REJOICE-Ov01 study
  • Exploring the outcome of dose optimisation analysis of R-DXd in patients with PROC